An expert consensus for the adjustment of treatment strategies in patients with chronic hepatitis B treated with non-first-line nucleos (t) ide analogues

Oral nucleos (t) ide analogues (NAs) is one of the main and efficient way for the treatment of chronic hepatitis B (CHB) . Considering the antiviral potency and drug resistance of domestic and foreign guidelines, NAs are divided into first-line and non-first-line drugs. “An Expert Consensus for the Adjustment of Treatment Strategies in Patients with Chronic Hepatitis B Treated with Non-first-line Nucleos (t) ide Analogues, ”is mainly aimed at those patients who are currently using non-first-line NAs drugs. In addition, how to standardize the adjustment to first-line NAs drugs of choice, which can strengthen the effectiveness of initial antiviral treatment to obtain better antiviral efficacy, and improve patient compliance, coinciding with the avoidance of occurrence of serious drug adverse reactions in patients with CHB is presented.